The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-ctdna-guided-atezolizumab-bladder-cancer-2026a1000fun?src=rss
Author :
Publish date : 2026-05-15 21:00:00
Copyright for syndicated content belongs to the linked Source.
